Paper Details

  1. Home
  2. Paper Details

Validation of a quantitative systems pharmacology model of calcium homeostasis using elagolix Phase 3 clinical trial data in women with endometriosis.

Author: MostafaNael M, NaderAhmed, NgJuki, NoertersheuserPeter, PolepallyAkshanth R, ShebleyMohamad, StodtmannSven, SuleimanAhmed A, WinzenborgInsa

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Validation StudyResearch to assess the validity and reliability of new measurement methods or diagnostic tests.

Overview

This study used a quantitative systems pharmacology (QSP) model to predict bone mineral density (BMD) changes in premenopausal women with endometriosis treated with elagolix. The QSP model successfully predicted BMD changes based on estradiol levels, validating the model for predicting the long-term impact of elagolix on BMD.
Paper Details　
Original Abstract of the Article :
Elagolix is a novel, oral gonadotropin-releasing hormone receptor antagonist indicated for the management of moderate to severe pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids. Consistent with its mechanism of action, elagolix exhibited dose-dependent...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8301592/

データ提供：米国国立医学図書館（NLM）

Elagolix: A New Oasis in the Desert of Endometriosis

The [treatment of endometriosis] can be a challenging journey, like navigating a vast and unforgiving desert. This study explores the [efficacy and safety] of [elagolix], a new [oral gonadotropin-releasing hormone receptor antagonist], for the [management of endometriosis pain]. Researchers validated a [quantitative systems pharmacology model] using [Phase 3 clinical trial data] to predict the [effects of elagolix] on [bone mineral density] during and after treatment.

Elagolix: A New Oasis in the Desert of Endometriosis

The study demonstrates the [effectiveness of elagolix] in [reducing endometriosis pain] and [managing heavy menstrual bleeding]. The [quantitative systems pharmacology model] successfully predicted the [impact of elagolix on bone mineral density], offering a [valuable tool] for [clinical decision-making].

Navigating the Desert of Endometriosis: Understanding Potential Side Effects

The study highlights the [potential side effects] of [elagolix], particularly its [impact on bone mineral density]. This information is crucial for [clinicians and patients] to make [informed decisions] about the [benefits and risks] of this [treatment option].

Dr. Camel's Conclusion

This study provides a valuable oasis in the desert of [endometriosis treatment]. While [elagolix] shows [promise] in [reducing pain and managing symptoms], understanding its [potential effects on bone health] is crucial. As always, [informed decision-making] and [close monitoring] are essential for navigating the desert of [endometriosis treatment].

Date :
  1. Date Completed 2022-02-14
  2. Date Revised 2022-02-14
Further Info :

Pubmed ID

33963686

DOI: Digital Object Identifier

PMC8301592

Related Literature

Article Analysis
・Effects of elagolix
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.